Recent advances in genome-editing technologies have unlocked the potential to directly correct pathogenic genetic mutations.

KB Home's US$55.60 share price signals that it might be 49% undervalued Our fair value estimate is 78% higher than KB Home's analyst price target of US$61.33 Today we will run through one way of ...

Binance will modify the collateral ratios for select tokens in Portfolio Margin accounts on July 15 and July 18, urging users ...

Plumas Bancorp (Nasdaq:PLBC), the parent company of Plumas Bank, today announced earnings during the second quarter of 2025 of $6.3 million or $1.07 per ...

Shopping lists at the ready. The bargain discount day will return to Dubai in July, where you can make the most of some ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to continue the development of a gene editing therapy for people with cystic fibrosis ...